Medical Devices & Consumables
Global Noninvasive Cancer Diagnostics Technology Market Research Report 2025
- Jan 09, 25
- ID: 797336
- Pages: 83
- Figures: 89
- Views: 1
The global market for Noninvasive Cancer Diagnostics Technology was valued at US$ 3780 million in the year 2024 and is projected to reach a revised size of US$ 6148 million by 2031, growing at a CAGR of 7.3% during the forecast period.
Noninvasive Cancer Diagnostics Technology is a process for the detection of disease through minimal incisions into the body. Noninvasive cancer diagnostic technologies provide fast and convenient procedures for noninvasive early detection of cancer and provide a valuable aid to the clinician and increased comfort to the patient.Noninvasive Cancer Diagnosis Technologies are used to identify breast, lung, blood, and other cancers.
The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics Technology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics Technology.
The Noninvasive Cancer Diagnostics Technology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Noninvasive Cancer Diagnostics Technology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Cancer Diagnostics Technology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
GRAIL, Inc
Guardant Health, Inc
Genomic Health, Inc.
Illumina, Inc
NeoGenomics Laboratories, Inc.
Biocept, Inc
Segment by Type
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others
Segment by Application
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics Technology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Noninvasive Cancer Diagnostics Technology is a process for the detection of disease through minimal incisions into the body. Noninvasive cancer diagnostic technologies provide fast and convenient procedures for noninvasive early detection of cancer and provide a valuable aid to the clinician and increased comfort to the patient.Noninvasive Cancer Diagnosis Technologies are used to identify breast, lung, blood, and other cancers.
The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.The global noninvasive cancer diagnostics technology market refers to the market for diagnostic technologies and tests that can detect and diagnose cancer without the need for invasive procedures such as biopsies or surgeries. Noninvasive cancer diagnostics utilize various methods, including imaging techniques, blood-based tests, and molecular biomarker analysis, to detect the presence of cancer cells or identify specific genetic mutations associated with different types of cancer.
Here are some key points about the global noninvasive cancer diagnostics technology market:
Market Size and Growth: The market for noninvasive cancer diagnostics technology has been growing due to the increasing prevalence of cancer worldwide and the need for early detection and accurate diagnosis. The market size is influenced by factors such as advancements in technology, rising awareness about cancer screening, and efforts to develop noninvasive alternatives to traditional cancer diagnostic methods.
Types of Noninvasive Cancer Diagnostics: The market includes various noninvasive diagnostic technologies, such as imaging techniques (e.g., mammography, MRI, CT scan, ultrasound), liquid biopsy tests (e.g., circulating tumor DNA, circulating tumor cells), and molecular biomarker analysis (e.g., gene expression profiling, proteomics, metabolomics). These technologies enable the detection, characterization, and monitoring of different types of cancers.
Applications: Noninvasive cancer diagnostics are utilized in the detection, screening, and monitoring of various types of cancers, including breast, lung, colorectal, prostate, and ovarian cancers, among others. These diagnostic tools can help in identifying cancer at early stages, monitoring treatment response, detecting cancer recurrence, and guiding targeted therapies.
Key Benefits and Advancements: Noninvasive cancer diagnostics offer several advantages over invasive methods, including reduced patient discomfort, lower risk of complications, and the potential for repeat testing. Recent advancements in technology, such as the development of liquid biopsy tests and molecular profiling techniques, have improved the sensitivity and specificity of noninvasive cancer diagnostics.
Geographic Distribution: The market for noninvasive cancer diagnostics technology is global, with variations in adoption and demand across different regions. Developed regions, such as North America and Europe, have well-established healthcare infrastructure, higher cancer prevalence, and greater awareness, driving the demand for noninvasive diagnostic technologies. The Asia Pacific region is also witnessing growth due to the increasing burden of cancer and improving healthcare access.
Industry Players: The global noninvasive cancer diagnostics technology market includes medical device companies, diagnostic laboratories, biotechnology companies, and research institutions. These entities play a crucial role in developing and commercializing noninvasive diagnostic technologies and tests, conducting clinical trials, and seeking regulatory approvals for their products.
Regulatory Landscape: The development and commercialization of noninvasive cancer diagnostics are subject to regulations and guidelines established by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These regulatory frameworks ensure the safety, efficacy, and quality of noninvasive diagnostic technologies.
In summary, the global noninvasive cancer diagnostics technology market is driven by the increasing demand for accurate, early detection and diagnosis of cancer. Noninvasive diagnostic technologies offer several advantages over invasive methods and have the potential to significantly impact cancer care. The market presents opportunities for companies to develop and market innovative noninvasive diagnostic technologies that improve patient outcomes, enable personalized treatment strategies, and contribute to the overall management of cancer.
This report aims to provide a comprehensive presentation of the global market for Noninvasive Cancer Diagnostics Technology, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Noninvasive Cancer Diagnostics Technology.
The Noninvasive Cancer Diagnostics Technology market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Noninvasive Cancer Diagnostics Technology market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Noninvasive Cancer Diagnostics Technology companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Precision Therapeutics
Affymetrix Inc.
Gen-Probe Incorporated
AVIVA Biosciences Corporation
A&G Pharmaceutical
BIOVIEW Inc.
Quest Diagnostics Incorporated
Digene Corporation
Laboratory Corporation of America Holdings.
GRAIL, Inc
Guardant Health, Inc
Genomic Health, Inc.
Illumina, Inc
NeoGenomics Laboratories, Inc.
Biocept, Inc
Segment by Type
Immunoassays
Molecular Diagnostics
Clinical Chemistry
Others
Segment by Application
Medical Device Manufacturing Company
Oncology Laboratories
Government and Private Research Institutions
Academic Institutions and Pharmaceutical Companies
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Noninvasive Cancer Diagnostics Technology company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immunoassays
1.2.3 Molecular Diagnostics
1.2.4 Clinical Chemistry
1.2.5 Others
1.3 Market by Application
1.3.1 Global Noninvasive Cancer Diagnostics Technology Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Medical Device Manufacturing Company
1.3.3 Oncology Laboratories
1.3.4 Government and Private Research Institutions
1.3.5 Academic Institutions and Pharmaceutical Companies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Cancer Diagnostics Technology Market Perspective (2020-2031)
2.2 Global Noninvasive Cancer Diagnostics Technology Growth Trends by Region
2.2.1 Global Noninvasive Cancer Diagnostics Technology Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Noninvasive Cancer Diagnostics Technology Historic Market Size by Region (2020-2025)
2.2.3 Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Region (2026-2031)
2.3 Noninvasive Cancer Diagnostics Technology Market Dynamics
2.3.1 Noninvasive Cancer Diagnostics Technology Industry Trends
2.3.2 Noninvasive Cancer Diagnostics Technology Market Drivers
2.3.3 Noninvasive Cancer Diagnostics Technology Market Challenges
2.3.4 Noninvasive Cancer Diagnostics Technology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Cancer Diagnostics Technology Players by Revenue
3.1.1 Global Top Noninvasive Cancer Diagnostics Technology Players by Revenue (2020-2025)
3.1.2 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Players (2020-2025)
3.2 Global Noninvasive Cancer Diagnostics Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Noninvasive Cancer Diagnostics Technology Revenue
3.4 Global Noninvasive Cancer Diagnostics Technology Market Concentration Ratio
3.4.1 Global Noninvasive Cancer Diagnostics Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Cancer Diagnostics Technology Revenue in 2024
3.5 Global Key Players of Noninvasive Cancer Diagnostics Technology Head office and Area Served
3.6 Global Key Players of Noninvasive Cancer Diagnostics Technology, Product and Application
3.7 Global Key Players of Noninvasive Cancer Diagnostics Technology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Cancer Diagnostics Technology Breakdown Data by Type
4.1 Global Noninvasive Cancer Diagnostics Technology Historic Market Size by Type (2020-2025)
4.2 Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Type (2026-2031)
5 Noninvasive Cancer Diagnostics Technology Breakdown Data by Application
5.1 Global Noninvasive Cancer Diagnostics Technology Historic Market Size by Application (2020-2025)
5.2 Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
6.2 North America Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
6.4 North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
7.2 Europe Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
7.4 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025)
8.4 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
9.2 Latin America Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
9.4 Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
10.4 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision Therapeutics
11.1.1 Precision Therapeutics Company Details
11.1.2 Precision Therapeutics Business Overview
11.1.3 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Introduction
11.1.4 Precision Therapeutics Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.1.5 Precision Therapeutics Recent Development
11.2 Affymetrix Inc.
11.2.1 Affymetrix Inc. Company Details
11.2.2 Affymetrix Inc. Business Overview
11.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.2.4 Affymetrix Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.2.5 Affymetrix Inc. Recent Development
11.3 Gen-Probe Incorporated
11.3.1 Gen-Probe Incorporated Company Details
11.3.2 Gen-Probe Incorporated Business Overview
11.3.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Introduction
11.3.4 Gen-Probe Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.3.5 Gen-Probe Incorporated Recent Development
11.4 AVIVA Biosciences Corporation
11.4.1 AVIVA Biosciences Corporation Company Details
11.4.2 AVIVA Biosciences Corporation Business Overview
11.4.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Introduction
11.4.4 AVIVA Biosciences Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.4.5 AVIVA Biosciences Corporation Recent Development
11.5 A&G Pharmaceutical
11.5.1 A&G Pharmaceutical Company Details
11.5.2 A&G Pharmaceutical Business Overview
11.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Introduction
11.5.4 A&G Pharmaceutical Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.5.5 A&G Pharmaceutical Recent Development
11.6 BIOVIEW Inc.
11.6.1 BIOVIEW Inc. Company Details
11.6.2 BIOVIEW Inc. Business Overview
11.6.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.6.4 BIOVIEW Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.6.5 BIOVIEW Inc. Recent Development
11.7 Quest Diagnostics Incorporated
11.7.1 Quest Diagnostics Incorporated Company Details
11.7.2 Quest Diagnostics Incorporated Business Overview
11.7.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Introduction
11.7.4 Quest Diagnostics Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.7.5 Quest Diagnostics Incorporated Recent Development
11.8 Digene Corporation
11.8.1 Digene Corporation Company Details
11.8.2 Digene Corporation Business Overview
11.8.3 Digene Corporation Noninvasive Cancer Diagnostics Technology Introduction
11.8.4 Digene Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.8.5 Digene Corporation Recent Development
11.9 Laboratory Corporation of America Holdings.
11.9.1 Laboratory Corporation of America Holdings. Company Details
11.9.2 Laboratory Corporation of America Holdings. Business Overview
11.9.3 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Introduction
11.9.4 Laboratory Corporation of America Holdings. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.9.5 Laboratory Corporation of America Holdings. Recent Development
11.10 GRAIL, Inc
11.10.1 GRAIL, Inc Company Details
11.10.2 GRAIL, Inc Business Overview
11.10.3 GRAIL, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.10.4 GRAIL, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.10.5 GRAIL, Inc Recent Development
11.11 Guardant Health, Inc
11.11.1 Guardant Health, Inc Company Details
11.11.2 Guardant Health, Inc Business Overview
11.11.3 Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.11.4 Guardant Health, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.11.5 Guardant Health, Inc Recent Development
11.12 Genomic Health, Inc.
11.12.1 Genomic Health, Inc. Company Details
11.12.2 Genomic Health, Inc. Business Overview
11.12.3 Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.12.4 Genomic Health, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.12.5 Genomic Health, Inc. Recent Development
11.13 Illumina, Inc
11.13.1 Illumina, Inc Company Details
11.13.2 Illumina, Inc Business Overview
11.13.3 Illumina, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.13.4 Illumina, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.13.5 Illumina, Inc Recent Development
11.14 NeoGenomics Laboratories, Inc.
11.14.1 NeoGenomics Laboratories, Inc. Company Details
11.14.2 NeoGenomics Laboratories, Inc. Business Overview
11.14.3 NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.14.4 NeoGenomics Laboratories, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.14.5 NeoGenomics Laboratories, Inc. Recent Development
11.15 Biocept, Inc
11.15.1 Biocept, Inc Company Details
11.15.2 Biocept, Inc Business Overview
11.15.3 Biocept, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.15.4 Biocept, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.15.5 Biocept, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Immunoassays
1.2.3 Molecular Diagnostics
1.2.4 Clinical Chemistry
1.2.5 Others
1.3 Market by Application
1.3.1 Global Noninvasive Cancer Diagnostics Technology Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Medical Device Manufacturing Company
1.3.3 Oncology Laboratories
1.3.4 Government and Private Research Institutions
1.3.5 Academic Institutions and Pharmaceutical Companies
1.3.6 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Noninvasive Cancer Diagnostics Technology Market Perspective (2020-2031)
2.2 Global Noninvasive Cancer Diagnostics Technology Growth Trends by Region
2.2.1 Global Noninvasive Cancer Diagnostics Technology Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Noninvasive Cancer Diagnostics Technology Historic Market Size by Region (2020-2025)
2.2.3 Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Region (2026-2031)
2.3 Noninvasive Cancer Diagnostics Technology Market Dynamics
2.3.1 Noninvasive Cancer Diagnostics Technology Industry Trends
2.3.2 Noninvasive Cancer Diagnostics Technology Market Drivers
2.3.3 Noninvasive Cancer Diagnostics Technology Market Challenges
2.3.4 Noninvasive Cancer Diagnostics Technology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Noninvasive Cancer Diagnostics Technology Players by Revenue
3.1.1 Global Top Noninvasive Cancer Diagnostics Technology Players by Revenue (2020-2025)
3.1.2 Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Players (2020-2025)
3.2 Global Noninvasive Cancer Diagnostics Technology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Noninvasive Cancer Diagnostics Technology Revenue
3.4 Global Noninvasive Cancer Diagnostics Technology Market Concentration Ratio
3.4.1 Global Noninvasive Cancer Diagnostics Technology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Noninvasive Cancer Diagnostics Technology Revenue in 2024
3.5 Global Key Players of Noninvasive Cancer Diagnostics Technology Head office and Area Served
3.6 Global Key Players of Noninvasive Cancer Diagnostics Technology, Product and Application
3.7 Global Key Players of Noninvasive Cancer Diagnostics Technology, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Noninvasive Cancer Diagnostics Technology Breakdown Data by Type
4.1 Global Noninvasive Cancer Diagnostics Technology Historic Market Size by Type (2020-2025)
4.2 Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Type (2026-2031)
5 Noninvasive Cancer Diagnostics Technology Breakdown Data by Application
5.1 Global Noninvasive Cancer Diagnostics Technology Historic Market Size by Application (2020-2025)
5.2 Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
6.2 North America Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
6.4 North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
7.2 Europe Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
7.4 Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
8.2 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025)
8.4 Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
9.2 Latin America Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
9.4 Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size (2020-2031)
10.2 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025)
10.4 Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Precision Therapeutics
11.1.1 Precision Therapeutics Company Details
11.1.2 Precision Therapeutics Business Overview
11.1.3 Precision Therapeutics Noninvasive Cancer Diagnostics Technology Introduction
11.1.4 Precision Therapeutics Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.1.5 Precision Therapeutics Recent Development
11.2 Affymetrix Inc.
11.2.1 Affymetrix Inc. Company Details
11.2.2 Affymetrix Inc. Business Overview
11.2.3 Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.2.4 Affymetrix Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.2.5 Affymetrix Inc. Recent Development
11.3 Gen-Probe Incorporated
11.3.1 Gen-Probe Incorporated Company Details
11.3.2 Gen-Probe Incorporated Business Overview
11.3.3 Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Introduction
11.3.4 Gen-Probe Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.3.5 Gen-Probe Incorporated Recent Development
11.4 AVIVA Biosciences Corporation
11.4.1 AVIVA Biosciences Corporation Company Details
11.4.2 AVIVA Biosciences Corporation Business Overview
11.4.3 AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Introduction
11.4.4 AVIVA Biosciences Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.4.5 AVIVA Biosciences Corporation Recent Development
11.5 A&G Pharmaceutical
11.5.1 A&G Pharmaceutical Company Details
11.5.2 A&G Pharmaceutical Business Overview
11.5.3 A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Introduction
11.5.4 A&G Pharmaceutical Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.5.5 A&G Pharmaceutical Recent Development
11.6 BIOVIEW Inc.
11.6.1 BIOVIEW Inc. Company Details
11.6.2 BIOVIEW Inc. Business Overview
11.6.3 BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.6.4 BIOVIEW Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.6.5 BIOVIEW Inc. Recent Development
11.7 Quest Diagnostics Incorporated
11.7.1 Quest Diagnostics Incorporated Company Details
11.7.2 Quest Diagnostics Incorporated Business Overview
11.7.3 Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Introduction
11.7.4 Quest Diagnostics Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.7.5 Quest Diagnostics Incorporated Recent Development
11.8 Digene Corporation
11.8.1 Digene Corporation Company Details
11.8.2 Digene Corporation Business Overview
11.8.3 Digene Corporation Noninvasive Cancer Diagnostics Technology Introduction
11.8.4 Digene Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.8.5 Digene Corporation Recent Development
11.9 Laboratory Corporation of America Holdings.
11.9.1 Laboratory Corporation of America Holdings. Company Details
11.9.2 Laboratory Corporation of America Holdings. Business Overview
11.9.3 Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Introduction
11.9.4 Laboratory Corporation of America Holdings. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.9.5 Laboratory Corporation of America Holdings. Recent Development
11.10 GRAIL, Inc
11.10.1 GRAIL, Inc Company Details
11.10.2 GRAIL, Inc Business Overview
11.10.3 GRAIL, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.10.4 GRAIL, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.10.5 GRAIL, Inc Recent Development
11.11 Guardant Health, Inc
11.11.1 Guardant Health, Inc Company Details
11.11.2 Guardant Health, Inc Business Overview
11.11.3 Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.11.4 Guardant Health, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.11.5 Guardant Health, Inc Recent Development
11.12 Genomic Health, Inc.
11.12.1 Genomic Health, Inc. Company Details
11.12.2 Genomic Health, Inc. Business Overview
11.12.3 Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.12.4 Genomic Health, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.12.5 Genomic Health, Inc. Recent Development
11.13 Illumina, Inc
11.13.1 Illumina, Inc Company Details
11.13.2 Illumina, Inc Business Overview
11.13.3 Illumina, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.13.4 Illumina, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.13.5 Illumina, Inc Recent Development
11.14 NeoGenomics Laboratories, Inc.
11.14.1 NeoGenomics Laboratories, Inc. Company Details
11.14.2 NeoGenomics Laboratories, Inc. Business Overview
11.14.3 NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Introduction
11.14.4 NeoGenomics Laboratories, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.14.5 NeoGenomics Laboratories, Inc. Recent Development
11.15 Biocept, Inc
11.15.1 Biocept, Inc Company Details
11.15.2 Biocept, Inc Business Overview
11.15.3 Biocept, Inc Noninvasive Cancer Diagnostics Technology Introduction
11.15.4 Biocept, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
11.15.5 Biocept, Inc Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Immunoassays
Table 3. Key Players of Molecular Diagnostics
Table 4. Key Players of Clinical Chemistry
Table 5. Key Players of Others
Table 6. Global Noninvasive Cancer Diagnostics Technology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Noninvasive Cancer Diagnostics Technology Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Noninvasive Cancer Diagnostics Technology Market Share by Region (2020-2025)
Table 10. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Noninvasive Cancer Diagnostics Technology Market Share by Region (2026-2031)
Table 12. Noninvasive Cancer Diagnostics Technology Market Trends
Table 13. Noninvasive Cancer Diagnostics Technology Market Drivers
Table 14. Noninvasive Cancer Diagnostics Technology Market Challenges
Table 15. Noninvasive Cancer Diagnostics Technology Market Restraints
Table 16. Global Noninvasive Cancer Diagnostics Technology Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Noninvasive Cancer Diagnostics Technology Market Share by Players (2020-2025)
Table 18. Global Top Noninvasive Cancer Diagnostics Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics Technology as of 2024)
Table 19. Ranking of Global Top Noninvasive Cancer Diagnostics Technology Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Noninvasive Cancer Diagnostics Technology Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Noninvasive Cancer Diagnostics Technology, Headquarters and Area Served
Table 22. Global Key Players of Noninvasive Cancer Diagnostics Technology, Product and Application
Table 23. Global Key Players of Noninvasive Cancer Diagnostics Technology, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Noninvasive Cancer Diagnostics Technology Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Type (2020-2025)
Table 27. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Type (2026-2031)
Table 29. Global Noninvasive Cancer Diagnostics Technology Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2020-2025)
Table 31. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2026-2031)
Table 33. North America Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 48. Precision Therapeutics Company Details
Table 49. Precision Therapeutics Business Overview
Table 50. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product
Table 51. Precision Therapeutics Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 52. Precision Therapeutics Recent Development
Table 53. Affymetrix Inc. Company Details
Table 54. Affymetrix Inc. Business Overview
Table 55. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product
Table 56. Affymetrix Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 57. Affymetrix Inc. Recent Development
Table 58. Gen-Probe Incorporated Company Details
Table 59. Gen-Probe Incorporated Business Overview
Table 60. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product
Table 61. Gen-Probe Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 62. Gen-Probe Incorporated Recent Development
Table 63. AVIVA Biosciences Corporation Company Details
Table 64. AVIVA Biosciences Corporation Business Overview
Table 65. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product
Table 66. AVIVA Biosciences Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 67. AVIVA Biosciences Corporation Recent Development
Table 68. A&G Pharmaceutical Company Details
Table 69. A&G Pharmaceutical Business Overview
Table 70. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product
Table 71. A&G Pharmaceutical Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 72. A&G Pharmaceutical Recent Development
Table 73. BIOVIEW Inc. Company Details
Table 74. BIOVIEW Inc. Business Overview
Table 75. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product
Table 76. BIOVIEW Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 77. BIOVIEW Inc. Recent Development
Table 78. Quest Diagnostics Incorporated Company Details
Table 79. Quest Diagnostics Incorporated Business Overview
Table 80. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product
Table 81. Quest Diagnostics Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 82. Quest Diagnostics Incorporated Recent Development
Table 83. Digene Corporation Company Details
Table 84. Digene Corporation Business Overview
Table 85. Digene Corporation Noninvasive Cancer Diagnostics Technology Product
Table 86. Digene Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 87. Digene Corporation Recent Development
Table 88. Laboratory Corporation of America Holdings. Company Details
Table 89. Laboratory Corporation of America Holdings. Business Overview
Table 90. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product
Table 91. Laboratory Corporation of America Holdings. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 92. Laboratory Corporation of America Holdings. Recent Development
Table 93. GRAIL, Inc Company Details
Table 94. GRAIL, Inc Business Overview
Table 95. GRAIL, Inc Noninvasive Cancer Diagnostics Technology Product
Table 96. GRAIL, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 97. GRAIL, Inc Recent Development
Table 98. Guardant Health, Inc Company Details
Table 99. Guardant Health, Inc Business Overview
Table 100. Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Product
Table 101. Guardant Health, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 102. Guardant Health, Inc Recent Development
Table 103. Genomic Health, Inc. Company Details
Table 104. Genomic Health, Inc. Business Overview
Table 105. Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Product
Table 106. Genomic Health, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 107. Genomic Health, Inc. Recent Development
Table 108. Illumina, Inc Company Details
Table 109. Illumina, Inc Business Overview
Table 110. Illumina, Inc Noninvasive Cancer Diagnostics Technology Product
Table 111. Illumina, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 112. Illumina, Inc Recent Development
Table 113. NeoGenomics Laboratories, Inc. Company Details
Table 114. NeoGenomics Laboratories, Inc. Business Overview
Table 115. NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Product
Table 116. NeoGenomics Laboratories, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 117. NeoGenomics Laboratories, Inc. Recent Development
Table 118. Biocept, Inc Company Details
Table 119. Biocept, Inc Business Overview
Table 120. Biocept, Inc Noninvasive Cancer Diagnostics Technology Product
Table 121. Biocept, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 122. Biocept, Inc Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Technology Picture
Figure 2. Global Noninvasive Cancer Diagnostics Technology Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Noninvasive Cancer Diagnostics Technology Market Share by Type: 2024 VS 2031
Figure 4. Immunoassays Features
Figure 5. Molecular Diagnostics Features
Figure 6. Clinical Chemistry Features
Figure 7. Others Features
Figure 8. Global Noninvasive Cancer Diagnostics Technology Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Noninvasive Cancer Diagnostics Technology Market Share by Application: 2024 VS 2031
Figure 10. Medical Device Manufacturing Company Case Studies
Figure 11. Oncology Laboratories Case Studies
Figure 12. Government and Private Research Institutions Case Studies
Figure 13. Academic Institutions and Pharmaceutical Companies Case Studies
Figure 14. Others Case Studies
Figure 15. Noninvasive Cancer Diagnostics Technology Report Years Considered
Figure 16. Global Noninvasive Cancer Diagnostics Technology Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Noninvasive Cancer Diagnostics Technology Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Noninvasive Cancer Diagnostics Technology Market Share by Region: 2024 VS 2031
Figure 19. Global Noninvasive Cancer Diagnostics Technology Market Share by Players in 2024
Figure 20. Global Top Noninvasive Cancer Diagnostics Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics Technology as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Noninvasive Cancer Diagnostics Technology Revenue in 2024
Figure 22. North America Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 24. United States Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 28. Germany Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Share by Region (2020-2031)
Figure 36. China Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 44. Mexico Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 48. Turkey Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Precision Therapeutics Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 52. Affymetrix Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 53. Gen-Probe Incorporated Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 54. AVIVA Biosciences Corporation Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 55. A&G Pharmaceutical Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 56. BIOVIEW Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 57. Quest Diagnostics Incorporated Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 58. Digene Corporation Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 59. Laboratory Corporation of America Holdings. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 60. GRAIL, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 61. Guardant Health, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 62. Genomic Health, Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 63. Illumina, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 64. NeoGenomics Laboratories, Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 65. Biocept, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Table 1. Global Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Immunoassays
Table 3. Key Players of Molecular Diagnostics
Table 4. Key Players of Clinical Chemistry
Table 5. Key Players of Others
Table 6. Global Noninvasive Cancer Diagnostics Technology Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Noninvasive Cancer Diagnostics Technology Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 8. Global Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025) & (US$ Million)
Table 9. Global Noninvasive Cancer Diagnostics Technology Market Share by Region (2020-2025)
Table 10. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 11. Global Noninvasive Cancer Diagnostics Technology Market Share by Region (2026-2031)
Table 12. Noninvasive Cancer Diagnostics Technology Market Trends
Table 13. Noninvasive Cancer Diagnostics Technology Market Drivers
Table 14. Noninvasive Cancer Diagnostics Technology Market Challenges
Table 15. Noninvasive Cancer Diagnostics Technology Market Restraints
Table 16. Global Noninvasive Cancer Diagnostics Technology Revenue by Players (2020-2025) & (US$ Million)
Table 17. Global Noninvasive Cancer Diagnostics Technology Market Share by Players (2020-2025)
Table 18. Global Top Noninvasive Cancer Diagnostics Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics Technology as of 2024)
Table 19. Ranking of Global Top Noninvasive Cancer Diagnostics Technology Companies by Revenue (US$ Million) in 2024
Table 20. Global 5 Largest Players Market Share by Noninvasive Cancer Diagnostics Technology Revenue (CR5 and HHI) & (2020-2025)
Table 21. Global Key Players of Noninvasive Cancer Diagnostics Technology, Headquarters and Area Served
Table 22. Global Key Players of Noninvasive Cancer Diagnostics Technology, Product and Application
Table 23. Global Key Players of Noninvasive Cancer Diagnostics Technology, Date of Enter into This Industry
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Noninvasive Cancer Diagnostics Technology Market Size by Type (2020-2025) & (US$ Million)
Table 26. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Type (2020-2025)
Table 27. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 28. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Type (2026-2031)
Table 29. Global Noninvasive Cancer Diagnostics Technology Market Size by Application (2020-2025) & (US$ Million)
Table 30. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2020-2025)
Table 31. Global Noninvasive Cancer Diagnostics Technology Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 32. Global Noninvasive Cancer Diagnostics Technology Revenue Market Share by Application (2026-2031)
Table 33. North America Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 34. North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 35. North America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 36. Europe Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 37. Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 38. Europe Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 39. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 40. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2020-2025) & (US$ Million)
Table 41. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size by Region (2026-2031) & (US$ Million)
Table 42. Latin America Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 43. Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 44. Latin America Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 45. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 46. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2020-2025) & (US$ Million)
Table 47. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size by Country (2026-2031) & (US$ Million)
Table 48. Precision Therapeutics Company Details
Table 49. Precision Therapeutics Business Overview
Table 50. Precision Therapeutics Noninvasive Cancer Diagnostics Technology Product
Table 51. Precision Therapeutics Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 52. Precision Therapeutics Recent Development
Table 53. Affymetrix Inc. Company Details
Table 54. Affymetrix Inc. Business Overview
Table 55. Affymetrix Inc. Noninvasive Cancer Diagnostics Technology Product
Table 56. Affymetrix Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 57. Affymetrix Inc. Recent Development
Table 58. Gen-Probe Incorporated Company Details
Table 59. Gen-Probe Incorporated Business Overview
Table 60. Gen-Probe Incorporated Noninvasive Cancer Diagnostics Technology Product
Table 61. Gen-Probe Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 62. Gen-Probe Incorporated Recent Development
Table 63. AVIVA Biosciences Corporation Company Details
Table 64. AVIVA Biosciences Corporation Business Overview
Table 65. AVIVA Biosciences Corporation Noninvasive Cancer Diagnostics Technology Product
Table 66. AVIVA Biosciences Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 67. AVIVA Biosciences Corporation Recent Development
Table 68. A&G Pharmaceutical Company Details
Table 69. A&G Pharmaceutical Business Overview
Table 70. A&G Pharmaceutical Noninvasive Cancer Diagnostics Technology Product
Table 71. A&G Pharmaceutical Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 72. A&G Pharmaceutical Recent Development
Table 73. BIOVIEW Inc. Company Details
Table 74. BIOVIEW Inc. Business Overview
Table 75. BIOVIEW Inc. Noninvasive Cancer Diagnostics Technology Product
Table 76. BIOVIEW Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 77. BIOVIEW Inc. Recent Development
Table 78. Quest Diagnostics Incorporated Company Details
Table 79. Quest Diagnostics Incorporated Business Overview
Table 80. Quest Diagnostics Incorporated Noninvasive Cancer Diagnostics Technology Product
Table 81. Quest Diagnostics Incorporated Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 82. Quest Diagnostics Incorporated Recent Development
Table 83. Digene Corporation Company Details
Table 84. Digene Corporation Business Overview
Table 85. Digene Corporation Noninvasive Cancer Diagnostics Technology Product
Table 86. Digene Corporation Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 87. Digene Corporation Recent Development
Table 88. Laboratory Corporation of America Holdings. Company Details
Table 89. Laboratory Corporation of America Holdings. Business Overview
Table 90. Laboratory Corporation of America Holdings. Noninvasive Cancer Diagnostics Technology Product
Table 91. Laboratory Corporation of America Holdings. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 92. Laboratory Corporation of America Holdings. Recent Development
Table 93. GRAIL, Inc Company Details
Table 94. GRAIL, Inc Business Overview
Table 95. GRAIL, Inc Noninvasive Cancer Diagnostics Technology Product
Table 96. GRAIL, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 97. GRAIL, Inc Recent Development
Table 98. Guardant Health, Inc Company Details
Table 99. Guardant Health, Inc Business Overview
Table 100. Guardant Health, Inc Noninvasive Cancer Diagnostics Technology Product
Table 101. Guardant Health, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 102. Guardant Health, Inc Recent Development
Table 103. Genomic Health, Inc. Company Details
Table 104. Genomic Health, Inc. Business Overview
Table 105. Genomic Health, Inc. Noninvasive Cancer Diagnostics Technology Product
Table 106. Genomic Health, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 107. Genomic Health, Inc. Recent Development
Table 108. Illumina, Inc Company Details
Table 109. Illumina, Inc Business Overview
Table 110. Illumina, Inc Noninvasive Cancer Diagnostics Technology Product
Table 111. Illumina, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 112. Illumina, Inc Recent Development
Table 113. NeoGenomics Laboratories, Inc. Company Details
Table 114. NeoGenomics Laboratories, Inc. Business Overview
Table 115. NeoGenomics Laboratories, Inc. Noninvasive Cancer Diagnostics Technology Product
Table 116. NeoGenomics Laboratories, Inc. Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 117. NeoGenomics Laboratories, Inc. Recent Development
Table 118. Biocept, Inc Company Details
Table 119. Biocept, Inc Business Overview
Table 120. Biocept, Inc Noninvasive Cancer Diagnostics Technology Product
Table 121. Biocept, Inc Revenue in Noninvasive Cancer Diagnostics Technology Business (2020-2025) & (US$ Million)
Table 122. Biocept, Inc Recent Development
Table 123. Research Programs/Design for This Report
Table 124. Key Data Information from Secondary Sources
Table 125. Key Data Information from Primary Sources
Table 126. Authors List of This Report
List of Figures
Figure 1. Noninvasive Cancer Diagnostics Technology Picture
Figure 2. Global Noninvasive Cancer Diagnostics Technology Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Noninvasive Cancer Diagnostics Technology Market Share by Type: 2024 VS 2031
Figure 4. Immunoassays Features
Figure 5. Molecular Diagnostics Features
Figure 6. Clinical Chemistry Features
Figure 7. Others Features
Figure 8. Global Noninvasive Cancer Diagnostics Technology Market Size by Application (2020-2031) & (US$ Million)
Figure 9. Global Noninvasive Cancer Diagnostics Technology Market Share by Application: 2024 VS 2031
Figure 10. Medical Device Manufacturing Company Case Studies
Figure 11. Oncology Laboratories Case Studies
Figure 12. Government and Private Research Institutions Case Studies
Figure 13. Academic Institutions and Pharmaceutical Companies Case Studies
Figure 14. Others Case Studies
Figure 15. Noninvasive Cancer Diagnostics Technology Report Years Considered
Figure 16. Global Noninvasive Cancer Diagnostics Technology Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 17. Global Noninvasive Cancer Diagnostics Technology Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 18. Global Noninvasive Cancer Diagnostics Technology Market Share by Region: 2024 VS 2031
Figure 19. Global Noninvasive Cancer Diagnostics Technology Market Share by Players in 2024
Figure 20. Global Top Noninvasive Cancer Diagnostics Technology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Noninvasive Cancer Diagnostics Technology as of 2024)
Figure 21. The Top 10 and 5 Players Market Share by Noninvasive Cancer Diagnostics Technology Revenue in 2024
Figure 22. North America Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. North America Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 24. United States Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 25. Canada Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. Europe Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. Europe Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 28. Germany Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. France Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. U.K. Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Italy Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Russia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 33. Nordic Countries Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. Asia-Pacific Noninvasive Cancer Diagnostics Technology Market Share by Region (2020-2031)
Figure 36. China Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. Japan Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. South Korea Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Southeast Asia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. India Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 41. Australia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Latin America Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Latin America Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 44. Mexico Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 45. Brazil Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. Middle East & Africa Noninvasive Cancer Diagnostics Technology Market Share by Country (2020-2031)
Figure 48. Turkey Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 49. Saudi Arabia Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 50. UAE Noninvasive Cancer Diagnostics Technology Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 51. Precision Therapeutics Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 52. Affymetrix Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 53. Gen-Probe Incorporated Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 54. AVIVA Biosciences Corporation Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 55. A&G Pharmaceutical Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 56. BIOVIEW Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 57. Quest Diagnostics Incorporated Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 58. Digene Corporation Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 59. Laboratory Corporation of America Holdings. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 60. GRAIL, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 61. Guardant Health, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 62. Genomic Health, Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 63. Illumina, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 64. NeoGenomics Laboratories, Inc. Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 65. Biocept, Inc Revenue Growth Rate in Noninvasive Cancer Diagnostics Technology Business (2020-2025)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Food Grade FIBC Bulk Bags Market Research Report 2025
Jan 09, 25
Global Standard FIBC Market Research Report 2025
Jan 09, 25
Global Mammoplasty Retractors Market Research Report 2025
Jan 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232